Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Zandbergen, G.
Right arrow Articles by Daha, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Zandbergen, G.
Right arrow Articles by Daha, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 13, Issue 12 3058-3064, Copyright © 1998 by Oxford University Press


ORIGINAL ARTICLES

Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89

G van Zandbergen, C van Kooten, N Mohamad, T Reterink, J de Fijter, J van de Winkel and M Daha
Department of Nephrology, Leiden University Medical Center, Building 1, C3P, PO Box 9600, 2300 RC, Leiden, The Netherlands; Department of Immunology, University Hospital, Utrecht, The Netherlands; Medarex Europe, Utrecht, The Netherlands; Corresponding author

Background. Primary IgA nephropathy (IgAN) is associated with elevated levels of circulating IgA and is characterized by deposition of primarily IgA1 in the renal mesangium. It has not yet been clarified which mechanisms govern the deposition of IgA1 in the mesangium. One of the factors which may play a role in trapping of IgA in the mesangial area is the interaction of IgA with specific IgA receptors (Fc&agr;R, CD89) on the mesangial cells. Methods. In the present study IgA derived from patients with IgAN and controls was investigated for its interaction with human CD89, expressed on the surface of the murine B cell line IIA1.6. Results. IgA binding to Cd89 expressing cells was specific, concentration dependent and binding of dIgA and pIgA occurred in a more efficient fashion than that of mIgA. IgA binding to CD89 directly from serum of patients compared to controls showed no significant difference. However these experiments are affected by differences in IgA concentration and combinations of different sizes of IgA. Using purified fractions of mIgA, dIgA, and pIgA isolated from serum, a significantly reduced binding of mIgA to CD89 from patients compared to controls was observed. Finally, the binding of aIgA2 to CD89 was less inhibited using mIgA from patients with IgAN compared to controls. Conclusions. The reduced binding of mIgA to CD89 seems to contradict a direct role for CD89 in deposition of IgA. However reduced binding of mIgA to CD89 may affect IgA clearance, leading to higher serum IgA. Furthermore, since it has been demonstrated that mIgA can interfere with binding of di- and pIgA deposition in the mesangial area. Keywords: CD89; Fc receptor IgA; IgAN
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
J. Barratt and J. Feehally
IgA Nephropathy
J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2088 - 2097.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
P. J. M. van der Boog, C. van Kooten, A. van Seggelen, M. Mallat, N. Klar-Mohamad, J. W. de Fijter, and M. R. Daha
An increased polymeric IgA level is not a prognostic marker for progressive IgA nephropathy
Nephrol. Dial. Transplant., October 1, 2004; 19(10): 2487 - 2493.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
K. N. Lai, L. Y. Y. Chan, S. C. W. Tang, A. W. L. Tsang, H. Guo, K. C. Tse, T. Yip, and J. C. K. Leung
Characteristics of Polymeric {lambda}-IgA Binding to Leukocytes in IgA Nephropathy
J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2309 - 2319.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Roos, L. H. Bouwman, D. J. van Gijlswijk-Janssen, M. C. Faber-Krol, G. L. Stahl, and M. R. Daha
Human IgA Activates the Complement System Via the Mannan-Binding Lectin Pathway
J. Immunol., September 1, 2001; 167(5): 2861 - 2868.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. D. Wines, C. T. Sardjono, H. M. Trist, C.-S. Lay, and P. M. Hogarth
The Interaction of Fc{{alpha}}RI with IgA and Its Implications for Ligand Binding by Immunoreceptors of the Leukocyte Receptor Cluster
J. Immunol., February 1, 2001; 166(3): 1781 - 1789.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. van Zandbergen, R. Westerhuis, N. K. Mohamad, J. G. J. van de Winkel, M. R. Daha, and C. van Kooten
Crosslinking of the Human Fc Receptor for IgA (Fc{alpha}RI/CD89) Triggers FcR {gamma}-Chain-Dependent Shedding of Soluble CD89
J. Immunol., December 1, 1999; 163(11): 5806 - 5812.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
H. Craig Morton, G. van Zandbergen, C. van Kooten, C. J. Howard, J. G. J. van de Winkel, and P. Brandtzaeg
Immunoglobulin-binding Sites of Human Fc{alpha}RI (CD89) and Bovine Fc{gamma}2R Are Located in their Membrane-distal Extracellular Domains
J. Exp. Med., June 7, 1999; 189(11): 1715 - 1722.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.